IGM Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 246.42 million compared to USD 221.1 million a year ago. Basic loss per share from continuing operations was USD 4.71 compared to USD 5.32 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.34 USD | -7.71% | -7.25% | +12.39% |
05-09 | RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk | MT |
05-08 | Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.39% | 551M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- IGMS Stock
- News IGM Biosciences, Inc.
- IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023